^
    Back
    Association details:
    Biomarker:GOPC-ROS1 fusion
    Cancer:Glioblastoma
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Eur J Cancer
    Title:

    Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis

    Published date:
    06/22/2023
    Excerpt:
    In our series, one patient with ROS1-GOPC fusion had a durable complete response to second-line entrectinib.
    DOI:
    https://doi.org/10.1016/j.ejca.2023.112959